Diabetes, Vol 38, Issue 10 1320-1325, Copyright © 1989 by American Diabetes Association

ARTICLES

Life-table analysis of progression to diabetes of anti-insulin autoantibody-positive relatives of individuals with type I diabetes

AG Ziegler, R Ziegler, P Vardi, RA Jackson, JS Soeldner and GS Eisenbarth
Joslin Diabetes Center, Brigham and Women's Hospital, Boston, MA 02215.

Cytoplasmic islet cell antibody-negative (ICA-; less than 20 Juvenile Diabetes Foundation units, n = 1670) and ICA+ (n = 42) first-degree relatives of type I (insulin-dependent) diabetic individuals were studied for competitive insulin autoantibodies (CIAAs) with a radioassay. Overall, 3.7% of first-degree relatives (64 of 1712) were CIAA+. Of ICA- relatives, 2.7% (45 of 1670) exceeded the upper limit of our normal CIAA range (greater than 39 nU/ml), and 45% (19 of 42) of ICA+ relatives exceeded this normal range. Follow-up serums for repeat CIAA determination have been obtained from 16 of the nondiabetic CIAA+/ICA- individuals (time between samples, 0.4-5.8 yr). Fourteen of these 16 (87%) CIAA+/ICA- relatives were found to still be positive on follow-up, and 2 of the relatives who were positive on the first determination were negative on their follow-up test. With a mean follow-up of approximately 2 yr, 4 of 45 (9%) of the CIAA+/ICA- relatives, 5 of 23 (22%) of the ICA+/CIAA- relatives, and 12 of 19 (63%) of the CIAA+/ICA+ relatives developed diabetes. Life-table analysis indicated that, overall, 53% of CIAA+ relatives become diabetic after 5 yr of follow-up versus 65% of ICA+ relatives. Also by life-table analysis, the predicted risk after 5 yr of follow-up for progression to diabetes is 17% for CIAA+/ICA- relatives, 42% for ICA+/CIAA- relatives, and 77% for CIAA+/ICA+ relatives. The highest rate of progression to diabetes was found in ICA+ relatives with CIAA levels greater than 150 nU/ml (100% projected to be diabetic within 5 yr, P less than .008 vs. ICA+/CIAA- relatives).
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. M. Sosenko, J. P. Palmer, C. J. Greenbaum, J. Mahon, C. Cowie, J. P. Krischer, H. P. Chase, N. H. White, B. Buckingham, K. C. Herold, et al. Patterns of metabolic progression to type 1 diabetes in the diabetes prevention trial-type 1. Diabetes Care, March 1, 2006; 29(3): 643 - 649. [Abstract] [Full Text] [PDF]

				E. Melanitou, D. Devendra, E. Liu, D. Miao, and G. S. Eisenbarth Early and Quantal (by Litter) Expression of Insulin Autoantibodies in the Nonobese Diabetic Mice Predict Early Diabetes Onset J. Immunol., December 1, 2004; 173(11): 6603 - 6610. [Abstract] [Full Text] [PDF]

				P. Achenbach, K. Warncke, J. Reiter, H. E. Naserke, A. J.K. Williams, P. J. Bingley, E. Bonifacio, and A.-G. Ziegler Stratification of Type 1 Diabetes Risk on the Basis of Islet Autoantibody Characteristics Diabetes, February 1, 2004; 53(2): 384 - 392. [Abstract] [Full Text] [PDF]

				W. E. Winter, N. Harris, and D. Schatz Immunological Markers in the Diagnosis and Prediction of Autoimmune Type 1a Diabetes Clin. Diabetes, October 1, 2002; 20(4): 183 - 191. [Abstract] [Full Text] [PDF]

				Diabetes Prevention Trial-Type 1 Diabetes Study Gr Effects of Insulin in Relatives of Patients with Type 1 Diabetes Mellitus N. Engl. J. Med., May 30, 2002; 346(22): 1685 - 1691. [Abstract] [Full Text] [PDF]

				L. Yu, D. D. Cuthbertson, N. Maclaren, R. Jackson, J. P. Palmer, T. Orban, G. S. Eisenbarth, and J. P. Krischer Expression of GAD65 and Islet Cell Antibody (ICA512) Autoantibodies Among Cytoplasmic ICA+ Relatives Is Associated With Eligibility for the Diabetes Prevention Trial-Type 1 Diabetes, August 1, 2001; 50(8): 1735 - 1740. [Abstract] [Full Text] [PDF]

				N. Abiru, A. K. Maniatis, L. Yu, D. Miao, H. Moriyama, D. Wegmann, and G. S. Eisenbarth Peptide and Major Histocompatibility Complex-Specific Breaking of Humoral Tolerance to Native Insulin With the B9-23 Peptide in Diabetes-Prone and Normal Mice Diabetes, June 1, 2001; 50(6): 1274 - 1281. [Abstract] [Full Text]

				M. J Redondo, M. Rewers, L. Yu, S. Garg, C. C Pilcher, R. B Elliott, and G. S Eisenbarth Genetic determination of islet cell autoimmunity in monozygotic twin, dizygotic twin, and non-twin siblings of patients with type 1 diabetes: prospective twin study BMJ, March 13, 1999; 318(7185): 698 - 702. [Abstract] [Full Text]

				M Hummel, I Durinovic-Bello, E Bonifacio, V Lampasona, J Endl, S Fessele, F T. Bergh, C Trenkwalder, E Standl, and A-G Ziegler Humoral and cellular immune parameters before and during immunosuppressive therapy of a patient with stiff-man syndrome and insulin dependent diabetes mellitus J. Neurol. Neurosurg. Psychiatry, August 1, 1998; 65(2): 204 - 208. [Abstract] [Full Text]

				L. Yu, D. T. Robles, N. Abiru, P. Kaur, M. Rewers, K. Kelemen, and G. S. Eisenbarth Early expression of antiinsulin autoantibodies of humans and the NOD mouse: Evidence for early determination of subsequent diabetes PNAS, February 15, 2000; 97(4): 1701 - 1706. [Abstract] [Full Text] [PDF]